1. Home
  2. ALLO vs PERI Comparison

ALLO vs PERI Comparison

Compare ALLO & PERI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • PERI
  • Stock Information
  • Founded
  • ALLO 2017
  • PERI 1999
  • Country
  • ALLO United States
  • PERI Israel
  • Employees
  • ALLO N/A
  • PERI N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • PERI EDP Services
  • Sector
  • ALLO Health Care
  • PERI Technology
  • Exchange
  • ALLO Nasdaq
  • PERI Nasdaq
  • Market Cap
  • ALLO 431.9M
  • PERI 430.0M
  • IPO Year
  • ALLO 2018
  • PERI 2006
  • Fundamental
  • Price
  • ALLO $2.07
  • PERI $8.58
  • Analyst Decision
  • ALLO Buy
  • PERI Hold
  • Analyst Count
  • ALLO 12
  • PERI 5
  • Target Price
  • ALLO $10.06
  • PERI $10.17
  • AVG Volume (30 Days)
  • ALLO 2.5M
  • PERI 265.9K
  • Earning Date
  • ALLO 11-07-2024
  • PERI 02-05-2025
  • Dividend Yield
  • ALLO N/A
  • PERI N/A
  • EPS Growth
  • ALLO N/A
  • PERI N/A
  • EPS
  • ALLO N/A
  • PERI 0.93
  • Revenue
  • ALLO $43,000.00
  • PERI $602,939,000.00
  • Revenue This Year
  • ALLO N/A
  • PERI N/A
  • Revenue Next Year
  • ALLO N/A
  • PERI N/A
  • P/E Ratio
  • ALLO N/A
  • PERI $9.25
  • Revenue Growth
  • ALLO 26.47
  • PERI N/A
  • 52 Week Low
  • ALLO $1.83
  • PERI $7.47
  • 52 Week High
  • ALLO $5.78
  • PERI $31.60
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 41.06
  • PERI 46.91
  • Support Level
  • ALLO $1.83
  • PERI $8.48
  • Resistance Level
  • ALLO $2.09
  • PERI $9.09
  • Average True Range (ATR)
  • ALLO 0.14
  • PERI 0.28
  • MACD
  • ALLO -0.01
  • PERI -0.06
  • Stochastic Oscillator
  • ALLO 30.38
  • PERI 18.75

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

About PERI Perion Network Ltd.

Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.

Share on Social Networks: